Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 3 | 1 | 4 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 1 | 4 |
| 2001 | 1 | 4 | 5 |
| 2002 | 2 | 2 | 4 |
| 2004 | 2 | 5 | 7 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 8 | 4 | 12 |
| 2008 | 6 | 2 | 8 |
| 2009 | 7 | 2 | 9 |
| 2010 | 9 | 3 | 12 |
| 2011 | 6 | 4 | 10 |
| 2012 | 6 | 4 | 10 |
| 2013 | 7 | 5 | 12 |
| 2014 | 8 | 3 | 11 |
| 2015 | 9 | 10 | 19 |
| 2016 | 6 | 7 | 13 |
| 2017 | 14 | 10 | 24 |
| 2018 | 14 | 7 | 21 |
| 2019 | 12 | 8 | 20 |
| 2020 | 4 | 10 | 14 |
| 2021 | 4 | 8 | 12 |
| 2022 | 3 | 12 | 15 |
| 2023 | 0 | 9 | 9 |
| 2024 | 9 | 2 | 11 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2025 Aug 21; 393(8):774-785.
-
Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precis Oncol. 2025 May; 9:e2400859.
-
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. Gynecol Oncol. 2025 Apr; 195:66-74.
-
Nail unit melanoma treated with Mohs micrographic surgery: Technique, local recurrence rate, and surgical outcomes. J Am Acad Dermatol. 2025 May; 92(5):1072-1079.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug; 34(8):1283-1289.
-
Clinicopathologic Features of Oral Verrucous Carcinoma: A Systematic Review and Meta-Analysis. Ann Otol Rhinol Laryngol. 2025 Mar; 134(3):187-194.
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clin Cancer Res. 2024 Aug 01; 30(15):3167-3178.
-
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations. Lancet Oncol. 2024 Jul; 25(7):e308-e317.